Emerging treatments
Eravacycline
An intravenous fluorocycline antibiotic in the tetracycline class that has been approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of complicated intra-abdominal infections in adults. It is indicated for patients at risk of resistant organisms or if an antibiotic-resistant organism has been identified.
Imipenem/cilastatin/relebactam
This combination antibiotic has been approved by the FDA for adults with complicated intra-abdominal infections. It can be used to treat patients with resistant bacteria or at high risk of resistant infections. Results from a phase two clinical trial among patients with complicated intra-abdominal infection showed the combination was well tolerated, had a similar safety profile to imipenem-cilastatin alone, and provided coverage of >90% of carbapenem-resistant bacterial strains.[69]
Use of this content is subject to our disclaimer